Scopolamine butylbromide

Chemical properties

Crystalline Solid

Originator

Butylscopolamine,China Pharm

The Uses of Scopolamine butylbromide

Anticholinergic. Antispasmodic

The Uses of Scopolamine butylbromide

(?)-Scopolamine N-butyl bromide was used as standard in designing a procedure for quantification of compounds using CE-MS.⁸

What are the applications of Application

N-Butylscopolammonium Bromide is an anticholinergic and antispasmodic

Definition

ChEBI: Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic bromide salt and a quaternary ammonium salt. It contains a butylscopolamine.

Manufacturing Process

1300 g of scopolamine base and 350 g of n-butylbromide in 600 ml acetonitrile is heated at 65°C for 160 hours. The oil obtained is dissolved in methanol. The solution is cooled and crystalline scopolamine N-n-butylbromide is filtered. After recrystallization from methanol was obtained scopolamine N-n-butylbromide with melting point 142-144°C and [α]d 20 = -20.5° (3% solution in water); yield 65%.

Therapeutic Function

Anticholinergic, Spasmolytic, Antitussive

Biochem/physiol Actions

Competitive muscarinic acetylcholine receptor antagonist; antispasmodic.

Clinical Use

Symptomatic relief of gastrointestinal or genitourinary disorders due to smooth muscle spasm Bowel colic
Excessive respiratory secretions

Metabolism

The main metabolic pathway is the hydrolytic cleavage of the ester bond. Orally administered hyoscine butylbromide is excreted in the faeces and in the urine. Studies in man show that 2-5% of radioactive doses is eliminated renally after oral, and 0.7-1.6% after rectal administration. Approximately 90% of recovered radioactivity can be found in the faeces after oral administration. The urinary excretion of hyoscine butylbromide is less than 0.1% of the dose. The metabolites excreted via the renal route bind poorly to muscarinic receptors and are therefore not considered to contribute to the effect of the hyoscine butylbromide.